Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection

Vaccine

Volumn 28, Issue 12, 2010, Pages 2416-2427

  Seib, Kate L ^a   Oriente, Francesca ^a   Adu Bobie, Jeannette ^a   Montanari, Paolo ^a   Ferlicca, Francesca ^a   Giuliani, Marzia M ^a   Rappuoli, Rino ^a   Pizza, Mariagrazia ^a   Delany, Isabel ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

fHBP; GNA1030; GNA2091; GNA2132; Meningococcal vaccine antigens; NadA; Reverse vaccinology

Indexed keywords

BACTERIAL ANTIGEN; MENINGOCOCCUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIUM MUTANT; CONTROLLED STUDY; DISEASE MODEL; DRUG ACTIVITY; EX VIVO STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIGENS, BACTERIAL; BIOMASS; BLOOD BACTERICIDAL ACTIVITY; CLINICAL TRIALS AS TOPIC; COLONY COUNT, MICROBIAL; GENE DELETION; HUMANS; MENINGOCOCCAL VACCINES; MICROBIAL VIABILITY; MUTAGENESIS, INSERTIONAL; NEISSERIA MENINGITIDIS, SEROGROUP B; NEPHELOMETRY AND TURBIDIMETRY; RATS; RATS, WISTAR; STRESS, PHYSIOLOGICAL; VIRULENCE;

EID: 77249115642     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.082     Document Type: Article

References (48)

1. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., and Hughes J.M. Meningococcal disease. N Engl J Med 344 May (18) (2001) 1378-1388
2. Stephens D.S. Conquering the meningococcus. FEMS Microbiol Rev 31 January (1) (2007) 3-14
3. Rosenstein N.E., Perkins B.A., Stephens D.S., Lefkowitz L., Cartter M.L., Danila R., et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 180 December (6) (1999) 1894-1901
4. Noah N., and Henderson B. Surveillance of bacterial meningitis in Europe 1997/1998 (2002), Communicable Disease Surveillance Centre, London
5. Seib K.L., and Rappuoli R. Difficulties in developing neisserial vaccines. In: Genco C.A., and Wetzler L.M. (Eds). Neisseria: molecular mechanisms of pathogenesis (2010), Horizon Scientific Press, Norwich, UK 195-226
6. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27 Suppl. 2 (2009) B3-B12
7. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 103 July (29) (2006) 10834-10839
8. Martin D.R., Ruijne N., McCallum L., O'Hallahan J., and Oster P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 13 April (4) (2006) 486-491
9. Rappuoli R. The application of reverse vaccinology, Novartis MenB vaccine developed by design. 16th International Pathogenic Neisseria Conference. Rotterdam, The Netherlands (2008) 81. Abstr. www.IPNC2008.org
10. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177 July (1) (2006) 501-510
11. Granoff D.M., Welsch J.A., and Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 77 February (2) (2009) 764-769
12. Welsch J.A., Ram S., Koeberling O., and Granoff D.M. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 197 April (7) (2008) 1053-1061
13. Seib K.L., Serruto D., Oriente F., Delany I., Adu-Bobie J., Veggi D., et al. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 77 January (1) (2009) 292-299
14. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197 March (6) (2003) 789-799
15. Giuliani M.M., Santini L., Brunelli B., Biolchi A., Arico B., Di Marcello F., et al. The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun 73 February (2) (2005) 1151-1160
16. Bambini S., Muzzi A., Olcen P., Rappuoli R., Pizza M., and Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27 21 (2009) 2794-2803
17. Welsch J.A., Rossi R., Comanducci M., and Granoff D.M. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 172 May (9) (2004) 5606-5615
18. Comanducci M., Bambini S., Brunelli B., Adu-Bobie J., Arico B., Capecchi B., et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 195 June (11) (2002) 1445-1454
19. Capecchi B., Adu-Bobie J., Di Marcello F., Ciucchi L., Masignani V., Taddei A., et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 55 February (3) (2005) 687-698
20. Franzoso S., Mazzon C., Sztukowska M., Cecchini P., Kasic T., Capecchi B., et al. Human monocytes/macrophages are a target of Neisseria meningitidis Adhesin A (NadA). J Leukoc Biol 83 May (5) (2008) 1100-1110
21. Tavano R., Franzoso S., Cecchini P., Cartocci E., Oriente F., Arico B., et al. The membrane expression of Neisseria meningitidis adhesin A (NadA) increases the proimmune effects of MenB OMVs on human macrophages, compared with NadA-OMVs, without further stimulating their proinflammatory activity on circulating monocytes. J Leukoc Biol 86 July (1) (2009) 143-153
22. Mazzon C., Baldani-Guerra B., Cecchini P., Kasic T., Viola A., de Bernard M., et al. IFN-{gamma} and R-848 dependent activation of human monocyte-derived dendritic cells by Neisseria meningitidis adhesin A. J Immunol 179 September (6) (2007) 3904-3916
23. Comanducci M., Bambini S., Caugant D.A., Mora M., Brunelli B., Capecchi B., et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun 72 July (7) (2004) 4217-4223
24. Serruto D, Spadafina T, Ciucchi L, Lewis LA, Ram S, Tontini M, et al. Neisseria meningitidis GNA2132 is a heparin binding protein cleaved by NalP and human lactoferrin serine proteases; in preparation.
25. Welsch J.A., Moe G.R., Rossi R., Adu-Bobie J., Rappuoli R., and Granoff D.M. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 188 December (11) (2003) 1730-1740
26. Fu J., Bailey F.J., King J.J., Parker C.B., Robinett R.S., Kolodin D.G., et al. Recent advances in the large scale fermentation of Neisseria meningitidis group B for the production of an outer membrane protein complex. Biotechnology (NY) 13 February (2) (1995) 170-174
27. Sambrook J., Fritsch E.F., and Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. (1989), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
28. Ison C.A., Anwar N., Cole M.J., Galassini R., Heyderman R.S., Klein N.J., et al. Assessment of immune response to meningococcal disease: comparison of a whole-blood assay and the serum bactericidal assay. Microb Pathog 27 October (4) (1999) 207-214
29. Granoff D.M., Moe G.R., Giuliani M.M., Adu-Bobie J., Santini L., Brunelli B., et al. A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis. J Immunol 167 December (11) (2001) 6487-6496
30. Metruccio M.M.E., Pigozzi E., Roncarati D., Berlanda Scorza F., Norais N., Hill S.A., et al. A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathog 5 12 (2009) e1000710
31. Mader R., Zu'bi A., and Schonfeld S. Recurrent sterile arthritis following primary septic meningococcal arthritis. Clin Exp Rheumatol 12 September-October (5) (1994) 531-533
32. Philips B., Meguer J.-X., Redman J., and Baker E. Factors determining the appearance of glucose in upper and lower respiratory tract secretions. Intens Care Med 29 12 (2003) 2204-2210
33. Rogan M.P., Geraghty P., Greene C.M., O'Neill S.J., Taggart C.C., and McElvaney N.G. Antimicrobial proteins and polypeptides in pulmonary innate defence. Respir Res 7 1 (2006) 29
34. Jounblat R., Clark H., Eggleton P., Hawgood S., Andrew P.W., and Kadioglu A. The role of surfactant protein D in the colonisation of the respiratory tract and onset of bacteraemia during pneumococcal pneumonia. Respir Res 6 (2005) 126
35. Meyer T.F. Evasion mechanisms of pathogenic Neisseriae. Behring Inst Mitt 88 February (1991) 194-199
36. Nielsen H.E., Christensen K.C., Koch C., Thomsen B.S., Heegaard N.H., and Tranum-Jensen J. Hereditary, complete deficiency of complement factor H associated with recurrent meningococcal disease. Scand J Immunol 30 December (6) (1989) 711-718
37. Ram S., and Vogel U. Role of complement in defence against meningococcal infection. In: Frosch M., and Maiden M.C.J. (Eds). Handbook of meningococcal disease infection biology, vaccination, clinical management (2006), Wiley-VCH Verlag GmbH & Co., Weinheim 273-293
38. Mathew S., and Overturf G.D. Complement and properidin deficiencies in meningococcal disease. Pediatr Infect Dis J 25 March (3) (2006) 255-256
39. Haralambous E., Dolly S.O., Hibberd M.L., Litt D.J., Udalova I.A., O'Dwyer C., et al. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand J Infect Dis 38 9 (2006) 764-771
40. Beernink P.T., Welsch J.A., Bar-Lev M., Koeberling O., Comanducci M., and Granoff D.M. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate, factor H-binding protein. Infect Immun 76 June (9) (2008) 4232-4240
41. McNeil L.K., Murphy E., Zhao X.J., Guttmann S., Harris S., Scott A., et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 27 25-26 (2009) 3417-3421
42. Schneider M.C., Exley R.M., Ram S., Sim R.B., and Tang C.M. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol 15 May (5) (2007) 233-240
43. Santos G.F., Giuliani M., Santini L., Adu-Bobie J., Pizza M., Rappuoli R., et al. Investigation on the effect of immune selection on resistance to bactericidal antibodies to group B meningococci in vitro. Clin Vaccine Immunol 16 November (11) (2009) 1693-1695
44. Litt D.J., Savino S., Beddek A., Comanducci M., Sandiford C., Stevens J., et al. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis 190 October (8) (2004) 1488-1497
45. Jacobsson S., Molling P., and Olcen P. Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis. Vaccine 27 42 (2009) 5755-5759
46. Oriente F, Scarlato V, Delany I. Expression of factor H binding protein of meningococcus responds to oxygen-limitation through a dedicated Fnr-regulated promoter. J Bacteriol, in press.
47. Schielke S., Huebner C., Spatz C., Nagele V., Ackermann N., Frosch M., et al. Expression of the meningococcal adhesin NadA is controlled by a transcriptional regulator of the MarR family. Mol Microbiol 72 May (4) (2009) 1054-1067
48. Tettelin H., Saunders N.J., Heidelberg J., Jeffries A.C., Nelson K.E., Eisen J.A., et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287 March (5459) (2000) 1809-1815